Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
24.24
-1.47 (-5.72%)
Apr 24, 2026, 4:00 PM EDT - Market closed
Alto Neuroscience Employees
Alto Neuroscience had 68 employees as of December 31, 2025. The number of employees decreased by 8 or -10.53% compared to the previous year.
Employees
68
Change (1Y)
-8
Growth (1Y)
-10.53%
Revenue / Employee
n/a
Profits / Employee
-$929,971
Market Cap
849.68M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 68 | -8 | -10.53% |
| Dec 31, 2024 | 76 | 9 | 13.43% |
| Sep 30, 2024 | 88 | 27 | 44.26% |
| Jun 30, 2024 | 78 | 17 | 27.87% |
| Mar 31, 2024 | 67 | - | - |
| Sep 30, 2023 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,300 |
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| Phathom Pharmaceuticals | 371 |
| Xencor | 260 |
| Geron | 258 |
| Omeros | 175 |
| Janux Therapeutics | 109 |
ANRO News
- 3 days ago - Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - Business Wire
- 22 days ago - Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Business Wire
- 5 weeks ago - Alto Neuroscience Announces $120 Million Private Placement Financing - Business Wire
- 5 weeks ago - Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 weeks ago - Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - Business Wire
- 2 months ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
- 2 months ago - Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - Business Wire
- 2 months ago - Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Business Wire